|2.30||-0.1000||-4.17%||Vol 573.08K||1Y Perf -6.07%|
|Apr 9th, 2021 16:00 DELAYED|
|- -||-0.03 -1.30%|
|Target Price||6.60||Analyst Rating||Strong Buy 1.33|
|Potential %||186.96||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-50/-50||Value Ranking||+ 35.39|
|Insiders Value % 3/6/12 mo.||-100/80/80||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/82/82||Income Ranking||— -|
|Market Cap||110.50M||Earnings Rating||Neutral|
|Price Range Ratio 52W %||18.25||Earnings Date||12th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||12th May 2021|
|Estimated EPS Next Report||-0.17|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||2.15M|
|Avg. Monthly Volume||924.27K|
|Avg. Quarterly Volume||1.04M|
Cidara Therapeutics Inc. (NASDAQ: CDTX) stock closed at 2.3 per share at the end of the most recent trading day (a -4.17% change compared to the prior day closing price) with a volume of 575.65K shares and market capitalization of 110.50M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 68 people. Cidara Therapeutics Inc. CEO is Jeffrey Stein.
The one-year performance of Cidara Therapeutics Inc. stock is -6.07%, while year-to-date (YTD) performance is 15%. CDTX stock has a five-year performance of -82.9%. Its 52-week range is between 1.82 and 4.45, which gives CDTX stock a 52-week price range ratio of 18.25%
Cidara Therapeutics Inc. currently has a PE ratio of -1.50, a price-to-book (PB) ratio of 11.93, a price-to-sale (PS) ratio of 13.60, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -110.50%, a ROC of -134.93% and a ROE of -288.49%. The company’s profit margin is -%, its EBITDA margin is -631.20%, and its revenue ttm is $9.54 Million , which makes it $0.20 revenue per share.
Of the last four earnings reports from Cidara Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.17 for the next earnings report. Cidara Therapeutics Inc.’s next earnings report date is 12th May 2021.
The consensus rating of Wall Street analysts for Cidara Therapeutics Inc. is Strong Buy (1.33), with a target price of $6.6, which is +186.96% compared to the current price. The earnings rating for Cidara Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cidara Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cidara Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.99, ATR14 : 0.24, CCI20 : 11.43, Chaikin Money Flow : 0.05, MACD : -0.03, Money Flow Index : 17.92, ROC : -2.30, RSI : 53.67, STOCH (14,3) : 50.56, STOCH RSI : 1.00, UO : 62.97, Williams %R : -49.44), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cidara Therapeutics Inc. in the last 12-months were: James E. Levine (Buy at a value of $100 720), Jeffrey Stein (Buy at a value of $100 015), Jessica Oien (Sold 2 001 shares of value $4 828 ), Neil Abdollahian (Sold 4 337 shares of value $9 816 ), Paul Daruwala (Sold 3 461 shares of value $7 485 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.